Phase 3 Stomach Cancer Trial, Recruiting NCT06313567 Sponsor: Fudan University Condition: Stomach Cancer
Back to Stomach Cancer

Phase 3 Stomach Cancer Trial, Recruiting

NCT06313567
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years old
  • People who have been confirmed by laboratory testing to have a specific type of stomach cancer called primary adenocarcinoma, at stage III
  • People who have had a type of stomach surgery (gastrectomy) where all visible cancer was removed (called R0) along with an extensive removal of nearby lymph nodes (called D2 lymphadenectomy)
  • People with a good general health and activity level, rated 0 or 1 on a standard medical scale, and expected to live more than 6 months
  • People whose blood counts, liver function, kidney function, and heart tests all fall within acceptable ranges as defined by the trial

Who may not be able to join:

  • People who have previously received chemotherapy, radiotherapy, immunotherapy, or targeted therapy
  • People who have more than one primary cancer diagnosis
  • People who have serious heart, lung, kidney, or liver disease, or poorly controlled high blood pressure, diabetes, or mental health conditions
  • People for whom the complete surgical removal of cancer (R0 resection with D2 lymph node dissection) was not possible
  • People diagnosed with stage IV (advanced/spread) stomach cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 021-64175590

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
10 March 2024
Est. completion
10 March 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov